Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Risk adjusted net present value: What is the current valuation of Immutep's Eftilagimod Alfa?
Eftilagimod Alfa is a fusion protein commercialized by Immutep, with a leading Phase III program in Human Epidermal Growth Factor...